menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Regeneron to Report Q1 2025 Results, Host Conference on April 29

    GLOBENEWSWIRE

    Regeneron Science Talent Search 2025 Awards Over $1.8 Million

    GLOBENEWSWIRE

    Dupixent Shows Late-Breaking Ph3 Data In Bullous Pemphigoid

    PRESS RELEASE

    Linvoseltamab Gets CHMP Nod For Relapsed/Refractory MM

    GLOBENEWSWIRE

    Odronextamab BLA Accepted for FDA Review for Follicular Lymphoma

    GLOBENEWSWIRE

    Regeneron gene therapy improves hearing in 10 children

    PRESS RELEASE

    FDA Accepts sBLA for Dupilumab for bullous pemphigoid

    PRESS RELEASE

    Dupixent sBLA Gets FDA Priority Review For Bullous Pemphigoid

    GLOBENEWSWIRE

    Linvoseltamab BLA Accepted for FDA Review for Myeloma

    GLOBENEWSWIRE

    Regeneron Announces Investor Conference Presentations

    GLOBENEWSWIRE

    EYLEA HD 8 mg Ph 3 Results for Macular Edema Retinal Vein

    GLOBENEWSWIRE

    EYLEA HD® 8 mg Shows Durable Vision Gains in Wet AMD 3-Year Data

    GLOBENEWSWIRE

    Regeneron lays out bright future for newest blockbuster Libtayo

    FIERCE PHARMA

    Regeneron Reports Q4 & Full Year 2024 Financial & Operating Results

    GLOBENEWSWIRE

    Regeneron wins appeals court orders backing halt on Eylea biosimilars

    EXPRESSPHARMA

    Top 40 High School Scientists Compete At Regeneron Talent Search

    GLOBENEWSWIRE

    Regeneron has few answers for declining sales of Eylea HD

    FIERCE PHARMA

    Regeneron Expands DNA Database With Truveta, Health Systems

    GLOBENEWSWIRE

    Adjuvant Libtayo® Improves DFS In High-Risk CSCC In Phase 3 Trial

    GLOBENEWSWIRE

    Regeneron Highlights Clinical Pipeline Updates At Morgan Conference

    GLOBENEWSWIRE

    Regeneron To Announce Q4 And FY24 Results On February 4, 2025

    GLOBENEWSWIRE

    Regeneron buys London-based ocular biotech

    ENDPTS

    Regeneron snaps up eye biotech, snaring science but not staff

    FIERCE BIOTECH

    Regeneron forges ahead in factor XI despite field’s mixed results

    ENDPTS

    Regeneron anticoagulant bests enoxaparin, matches Eliquis

    FIERCE BIOTECH

    New treatments needed in chronic hand eczema

    FIERCE PHARMA

    Eylea HD passes test in retinal vein occlusion, teeing up filing

    FIERCE PHARMA

    Regeneron to expand high-dose Eylea`s label after Ph 3 win

    BIOSPACE

    Regeneron Announces Presentation at 43rd J.P. Morgan Health Conf.

    GLOBENEWSWIRE

    Regeneron Named to Dow Jones Sustainability Index

    GLOBENEWSWIRE

    Odronextamab Data Highlights Potential in Lymphoma Treatment

    GLOBENEWSWIRE

    Pozelimab+Cemdisiran Superior to Ravulizumab in Hemoglobinuria

    GLOBENEWSWIRE

    Medigene Receives Milestone Payment from Regeneron Pharma, Inc.

    GLOBENEWSWIRE

    Regeneron`s Ordspono Receives Approval in Europe

    EMA

    Regeneron Highlights Blood Cancer Pipeline at ASH

    GLOBENEWSWIRE

    Regeneron Announces Investor Conference Presentations

    GLOBENEWSWIRE

    Regeneron Reports Q3 2024 Financial and Operating Results

    GLOBENEWSWIRE

    Regeneron`s Biologic Inmazeb Receives Suppl Approval in US

    FDA

    Dupixent® Late-Breaking Phase 3 Data In Chronic Urticaria

    GLOBENEWSWIRE

    Amgen gears up to launch Eylea biosim as Regeneron plots appeal

    FIERCE PHARMA

    EYLEA HD® Injection Shows Gains In Diabetic Macular Edema.

    GLOBENEWSWIRE

    Regeneron and Sanofi’s Dupixent to Dominate COPD Biologics Market

    BIOSPACE

    Regeneron`s Biologic Eylea HD (Aflibercept) Receives Suppl Approval in US

    FDA

    Regeneron Pharma`s Biologic Eylea Receives Suppl Approval in US

    FDA

    Clearside`s CLS-AX excels in phase 2b trial, set for phase 3

    FIERCE PHARMA

    Dupixent takes pharma DTC top spot in September

    FIERCE PHARMA

    Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD

    BIOSPACE

    Dupixent Approved As First Biologic Medicine For COPD Patients

    GLOBENEWSWIRE

    Regeneron To Report Third Quarter 2024 Financial Results

    GLOBENEWSWIRE

    Regeneron loses bid to block Amgen`s Eylea biosim, sinking shares

    FIERCE PHARMA

    Amgen gets early win in Regeneron lawsuit over Eylea biosimilar

    REUTERS

    Dupixent Approved For Adolescents With Chronic Rhinosinusitis With Polyps

    GLOBENEWSWIRE

    Demy-Colton`s BioFuture 2024 To Feature Regeneron, IBM, Ipsen, And VCs

    BUSINESSWIRE

    Dupixent Phase 3 Trial Shows Improvement In Chronic Spontaneous Urticaria

    GLOBENEWSWIRE

    EYLEA HD Data At EURETINA Shows Long-term Durability And Safety

    GLOBENEWSWIRE

    Sanofi And Regeneron Show Data For Dupixent In Hives After FDA Rejection

    FIERCE PHARMA

    Regeneron To Highlight Progress At WCLC And ESMO

    GLOBENEWSWIRE

    Libtayo Demonstrates Durable Survival Benefit In Lung Cancer

    GLOBENEWSWIRE

    Sonoma Biotherapeutics Receives $45M Regeneron Milestone

    CONTRACT PHARMA

    ArsenalBio Snags Mega $325M Series C Round With Backing from Nvidia, Regeneron

    BIOSPACE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.